INTRODUCTION: PARP-1 plays important role in the BER (base excision repair) and maintenance of genomic integrity. Previous study found the Val762Ala genetic variant in the PARP-1 gene contributed to susceptibility of some cancers and decreased PARP-1 enzyme activity in response to oxidative damage. Helicobacter pylori (H. pylori) infection was thought to be one of the major causes of gastric cancer. In this study, we investigated the association between the PARP-1 Val762Ala polymorphism, CagA(+) H. pylori infection, and the risk for gastric cancer. METHODS: This hospital-based, case-control study was performed involving 556 individuals (236 cases with gastric cancer and 320 controls without evidence of neoplasm and gastrointestinal disease) using a PCR-RFLP method. Chi-square test and logistic regression analysis were used to count OR and 95% CI. RESULTS: 762Ala/Ala genotype was overrepresented in the cases (16.9%) compared with controls (10.3%), (OR, 1.942; 95% CI, 1.157-3.257, P = 0.011). Multivariate analysis showed that two factors were significantly associated with risk of gastric cancer, including CagA(+) H. pylori infection (OR, 2.562; 95% CI, 1.174-5.240, P = 0.037), PARP-1 762AA genotype (OR, 1.772; 95% CI, 1.065-3.867; P = 0.042). Stratification analysis indicated that among Cag(+) H. pylori positive subjects, 762Ala/Ala carriers had higher risk for developing gastric cancer compared with 762Val/Val carrier (OR, 2.337; 95% CI, 1.148-4.758; P = 0.017). CONCLUSION: PARP-1 762Ala/Ala could be a risk factor for gastric cancer in Han Chinese population; PARP-1 762Val/Ala polymorphism and Cag(+) H. pylori infection jointly contribute to higher risk for gastric cancer.
INTRODUCTION: PARP-1 plays important role in the BER (base excision repair) and maintenance of genomic integrity. Previous study found the Val762Ala genetic variant in the PARP-1 gene contributed to susceptibility of some cancers and decreased PARP-1 enzyme activity in response to oxidative damage. Helicobacter pylori (H. pylori) infection was thought to be one of the major causes of gastric cancer. In this study, we investigated the association between the PARP-1 Val762Ala polymorphism, CagA(+) H. pylori infection, and the risk for gastric cancer. METHODS: This hospital-based, case-control study was performed involving 556 individuals (236 cases with gastric cancer and 320 controls without evidence of neoplasm and gastrointestinal disease) using a PCR-RFLP method. Chi-square test and logistic regression analysis were used to count OR and 95% CI. RESULTS: 762Ala/Ala genotype was overrepresented in the cases (16.9%) compared with controls (10.3%), (OR, 1.942; 95% CI, 1.157-3.257, P = 0.011). Multivariate analysis showed that two factors were significantly associated with risk of gastric cancer, including CagA(+) H. pylori infection (OR, 2.562; 95% CI, 1.174-5.240, P = 0.037), PARP-1 762AA genotype (OR, 1.772; 95% CI, 1.065-3.867; P = 0.042). Stratification analysis indicated that among Cag(+) H. pylori positive subjects, 762Ala/Ala carriers had higher risk for developing gastric cancer compared with 762Val/Val carrier (OR, 2.337; 95% CI, 1.148-4.758; P = 0.017). CONCLUSION: PARP-1 762Ala/Ala could be a risk factor for gastric cancer in Han Chinese population; PARP-1 762Val/Ala polymorphism and Cag(+) H. pyloriinfection jointly contribute to higher risk for gastric cancer.
Authors: M Ohyauchi; A Imatani; M Yonechi; N Asano; A Miura; K Iijima; T Koike; H Sekine; S Ohara; T Shimosegawa Journal: Gut Date: 2005-03 Impact factor: 23.059
Authors: C M Simbulan-Rosenthal; B R Haddad; D S Rosenthal; Z Weaver; A Coleman; R Luo; H M Young; Z Q Wang; T Ried; M E Smulson Journal: Proc Natl Acad Sci U S A Date: 1999-11-09 Impact factor: 11.205
Authors: C Figueiredo; W Quint; N Nouhan; H van den Munckhof; P Herbrink; J Scherpenisse; W de Boer; P Schneeberger; G Perez-Perez; M J Blaser; L J van Doorn Journal: J Clin Microbiol Date: 2001-04 Impact factor: 5.948
Authors: Jae J Kim; Hong Tao; Emilia Carloni; Wai K Leung; David Y Graham; Antonia R Sepulveda Journal: Gastroenterology Date: 2002-08 Impact factor: 22.682
Authors: Kristin L Lockett; M Craig Hall; Jianfeng Xu; S Lilly Zheng; Marianne Berwick; Shu-Chun Chuang; Peter E Clark; Scott D Cramer; Kurt Lohman; Jennifer J Hu Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: M J Blaser; G I Perez-Perez; H Kleanthous; T L Cover; R M Peek; P H Chyou; G N Stemmermann; A Nomura Journal: Cancer Res Date: 1995-05-15 Impact factor: 12.701